This HTML5 document contains 106 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n19http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/AHFS/
n10http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n5http://linked.opendata.cz/resource/drugbank/company/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00218/identifier/chemspider/
n4http://linked.opendata.cz/resource/drugbank/dosage/
n17http://bio2rdf.org/drugbank:
n13http://linked.opendata.cz/resource/drugbank/drug/DB00218/identifier/wikipedia/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00218/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n26http://linked.opendata.cz/resource/drugbank/drug/DB00218/identifier/kegg-compound/
n25http://linked.opendata.cz/resource/drugbank/patent/
n27http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00218/identifier/bindingdb/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00218/identifier/pubchem-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/resource/drugbank/medicinal-product/
n9http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n30http://www.drugs.com/cdi/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00218/identifier/pubchem-substance/
n11http://linked.opendata.cz/resource/drugbank/property/
n31http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00218/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://linked.opendata.cz/resource/atc/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00218/identifier/national-drug-code-directory/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00218
rdf:type
n3:Drug
n3:description
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
n3:dosage
n4:271B5EC1-363D-11E5-9242-09173F13E4C5 n4:271B5EC2-363D-11E5-9242-09173F13E4C5 n4:271B5EC3-363D-11E5-9242-09173F13E4C5 n4:271B5EBE-363D-11E5-9242-09173F13E4C5 n4:271B5EBF-363D-11E5-9242-09173F13E4C5 n4:271B5EC0-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Ginsburg AS, Hooper N, Parrish N, Dooley KE, Dorman SE, Booth J, Diener-West M, Merz WG, Bishai WR, Sterling TR: Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis. 2003 Dec 1;37(11):1448-52. Epub 2003 Nov 4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14614666
n3:group
approved investigational
n3:halfLife
11.5-15.6 hours (single dose, oral)
n3:indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
n3:manufacturer
n5:271B5EB7-363D-11E5-9242-09173F13E4C5 n5:271B5EB8-363D-11E5-9242-09173F13E4C5 n5:271B5EB6-363D-11E5-9242-09173F13E4C5
owl:sameAs
n17:DB00218 n27:DB00218
dcterms:title
Moxifloxacin
adms:identifier
n13:Moxifloxacin n20:50146367 n21:134802 n22:46508509 n23:PA450555 n24:152946 n26:C07663 n28:0085-1733-01 n29:DB00218
n3:mechanismOfAction
The bactericidal action of moxifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.
n3:packager
n5:271B5EB5-363D-11E5-9242-09173F13E4C5 n5:271B5EAF-363D-11E5-9242-09173F13E4C5 n5:271B5EB0-363D-11E5-9242-09173F13E4C5 n5:271B5EAD-363D-11E5-9242-09173F13E4C5 n5:271B5EAE-363D-11E5-9242-09173F13E4C5 n5:271B5EB3-363D-11E5-9242-09173F13E4C5 n5:271B5EB4-363D-11E5-9242-09173F13E4C5 n5:271B5EB1-363D-11E5-9242-09173F13E4C5 n5:271B5EB2-363D-11E5-9242-09173F13E4C5 n5:271B5EA7-363D-11E5-9242-09173F13E4C5 n5:271B5EA8-363D-11E5-9242-09173F13E4C5 n5:271B5EA5-363D-11E5-9242-09173F13E4C5 n5:271B5EA6-363D-11E5-9242-09173F13E4C5 n5:271B5EAB-363D-11E5-9242-09173F13E4C5 n5:271B5EAC-363D-11E5-9242-09173F13E4C5 n5:271B5EA9-363D-11E5-9242-09173F13E4C5 n5:271B5EAA-363D-11E5-9242-09173F13E4C5 n5:271B5EA4-363D-11E5-9242-09173F13E4C5
n3:patent
n25:2342211 n25:4990517 n25:1340114 n25:6548079
n3:routeOfElimination
Approximately 45% of an oral or intravenous dose of moxifloxacin is excreted as unchanged drug (~20% in urine and ~25% in feces).
n3:synonym
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid Moxifloxacin
n3:toxicity
Symptoms of overdose include CNS and gastrointestinal effects such as decreased activity, somnolence, tremor, convulsions, vomiting, and diarrhea. The minimal lethal intravenous dose in mice and rats is 100 mg/kg.
n3:volumeOfDistribution
* 1.7 to 2.7 L/kg
n7:hasAHFSCode
n14:52-04-04 n14:08-12-18
n3:foodInteraction
Take without regard to meals. Drink liberally. Absorption is not affected by lipid-rich meals or yogourt.
n3:proteinBinding
50% bound to serum proteins, independent of drug concentration.
n3:salt
n3:synthesisReference
Manne Reddy, Sajja Eswaraiah, Vetukuri Venkata Naga Raju, Rapolu Kumar, Ningam Srinivasreddy, Vedantham Ravindra, "Crystalline form III of anhydrous moxifloxacin hydrochloride and a process for preparation thereof." U.S. Patent US20050137227, issued June 23, 2005.
n9:hasConcept
n10:M0273433
foaf:page
n19:vigamox.htm n30:moxifloxacin-drops.html n31:ave1540.shtml
n3:IUPAC-Name
n11:271B5EC8-363D-11E5-9242-09173F13E4C5
n3:InChI
n11:271B5ECE-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n11:271B5ECD-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n11:271B5ECA-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n11:271B5ECB-363D-11E5-9242-09173F13E4C5
n3:SMILES
n11:271B5ECC-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n11:271B5EC6-363D-11E5-9242-09173F13E4C5
n3:logP
n11:271B5EC4-363D-11E5-9242-09173F13E4C5 n11:271B5EC7-363D-11E5-9242-09173F13E4C5 n11:271B5EDF-363D-11E5-9242-09173F13E4C5
n3:logS
n11:271B5EC5-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n8:J01MA14 n8:S01AE07
n3:H-Bond-Acceptor-Count
n11:271B5ED4-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n11:271B5ED5-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n11:271B5ECF-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n11:271B5ED0-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n11:271B5ED2-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n11:271B5ED1-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n11:271B5ED3-363D-11E5-9242-09173F13E4C5
n3:absorption
Well absorbed from the gastrointestinal tract. Absolute oral bioavailability is approximately 90%. Food has little effect on absorption.
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
354812-41-2
n3:category
n3:clearance
* 12 +/- 2 L/hr
n3:containedIn
n6:271B5EBA-363D-11E5-9242-09173F13E4C5 n6:271B5EBB-363D-11E5-9242-09173F13E4C5 n6:271B5EB9-363D-11E5-9242-09173F13E4C5 n6:271B5EBC-363D-11E5-9242-09173F13E4C5 n6:271B5EBD-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n11:271B5EDA-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n11:271B5EDC-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n11:271B5EDD-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n11:271B5EDE-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n11:271B5ED9-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n11:271B5ED8-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n11:271B5EDB-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n11:271B5EC9-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n11:271B5ED6-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n11:271B5ED7-363D-11E5-9242-09173F13E4C5